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ABSTRACT 
Glycosidase inhibitors are important compounds that can interfere with several 
biosynthetic processes including N-linked glycosylation and the biosynthesis of several 
glycoproteins. Understanding the biogenesis of naturally occurring glycosidase 
inhibitors would be a crucial step towards the chemical synthesis of analogues of 
choice. This review focuses on the current knowledge regarding the biosynthesis of a 
series of polyhydroxylated saturated nitrogen heterocycles including nojirimycin and 
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1. Introduction 
Glycosydase inhibitors are a rapidly growing family of molecules mostly 
consisting of polyhydroxylated mono- and bicyclic saturated nitrogen heterocycles 
commonly referred to as iminosugars (Figure 1).[1-3] Compounds like nojirimycin 1, 1-
deoxynojirimycin 2, DMDP 3, castanospermine 4 or swainsonine 5 and their derivatives 
play crucial roles in the biological activities of some pharmaceutically important 
compounds. [4-6] 
 
Figure 1. Glycosidase inhibitors 
 
Nojirimycin 1 was originally isolated from cultures of several strands of 
Streptomyces [7,8] and Bacillus[9] and 1-deoxynojirimycin was isolated from plants of 
genus Morus.[10] Compounds 1 and 2 inhibit various glycosidases having important 
effects on the biosynthesis of membrane and secretory glycoproteins.[11] DMDP 3 can 
be isolated from the cyanobacterial genus Cylindrospermum and it is capable of 
effectively inhibiting digestive glycosidases.[12] The 6-deoxyderivative 4 has been 
isolated from Angylocalyx pynaertii and in contrast to other polyhydroxylated 
pyrrolidines it was found to be unique in inhibiting β–mannosidase.[13] 
Castanospermine 5 was first isolated from the seeds of Castanosperma australe[14] and 
it has demonstrated antiviral activity.[15,16] It is also known that castanospermine 
interfere with the metabolism of glycogen[17] and it inhibits several glycosidases.[18] 
Swainsonine 6 was first isolated from swainsona in Australia but it is also present in 
numerous plants and fungi. Compound 6 has antitumoral activity[19,20] although some 
clinical trials were discouraging.[21] Other natural pyrrolidine alkaloids like alexine 7, 
australine 8 and casuarine 9 have also been isolated from plants and 
microorganisms.[22] 
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Calystegines were found in the medicinal plant Atropa belladonna and consist of 
a nortropane skeleton with three or four hydroxyl groups (Figure 2). There are up to 14 
different structures of natural occurring calystegines isolated from a variety of vascular 
plants. They cannot be found in fungi or microorganisms. The chemistry and biology of 
calystegines including chemotaxonomy, biological activity and some insights on the 
biogenesis in the context of co-occurrence with tropane alkaloids have been compiled 
by Dräger in an excellent review[23] and a chapter book,[24] covering literature from 
1998 to middle 2003 and up to 2007, respectively. Since then there has not been 
relevant communications in the topic; so, in this review calystegines will not be treated 
and for previous work the reader is directed to the above mentioned reviews. 
 
Figure 2. Calystegines 
 
The interest in glycosidase inhibitors has increased enormously during the past 
two decades and the number of synthetic approaches to their preparation is extremely 
extensive and growing at a rapid rate.[25,26] One reason for this huge synthetic activity 
is the great variety of biological activity against different enzymes that can be found 
depending on the absolute configuration of the stereogenic centers bearing the hydroxyl 
groups.  
The mechanism of the various existing glycosidases is known to proceed 
through oxocarbenium-like transition structures[27,28] and it is well-accepted that 
inhibition of typical glycosidase inhibitors occur because such sugar mimics resemble 
the structural features of the transition state.[29] Different configurations as well as 
conformational restrictions in inhibitors help to a better recognition by the enzyme 
contributing to a higher inhibition activity.[30] 
In the large group of glycosidase inhibitors, synthetic studies have already been 
highlighted in several classes,[31-33] e.g. for pyrrolidines,[34,35] piperidines,[36,37] 
bicyclic compounds such as indolizidines[38] and pyrrolizidines[39,40] and imino 
disaccharides.[41,42] However, only a little is known about biosynthetic routes towards 
that sort of compounds. It can be expected that the knowledge of the biosynthetic 
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pathways can be used to manipulate the metabolite pattern of involved microorganisms, 
directing the fermentation process to produce desired metabolites.  
In this review, we summarize the current knowledge regarding the biosynthesis 
of naturally occurring glycosidase inhibitors. Semisynthetic studies on the structural and 
pharmaceutical properties of these compounds have been extensively reported and will 
not be covered here. Similarly, for detailed information of natural occurrence of 
discussed molecules and precise synthetic approaches the reader is referred to previous 
reviews. On the other hand, experimental evidences supporting the existence of various 
routes in microorganisms will be discussed. 
 
2. Biosynthesis of monocyclic compounds. Piperidines and pyrrolidines 
 Nojririmycin 1 has been isolated from a variety of microorganisms including S. 
roseochromogenes, S. lavendulae, S. nojiriensis and S. subrutilus. The last one, when 
grown on a glucose-containing soyabean medium produces both 1-
deoxymannojirimycin and 1-deoxynojirimycin. Experiments with deuterated glucose 
showed incorporation of deuterium at C-6 in both alkaloids indicating that the first step 
in the biosynthesis of both iminosugars is the isomerization of glucose to fructose. 
Accordingly, it is proposed mannojirimycin 17 as the first iminosugar to be formed.[43]  
In fact, when 6,6-[
2
H2]-glucose was employed, NMR analysis of deuterium 
labellled 1-deoxynojirimycin 2 showed that only the equatorial proton at C-1 had been 
replaced by deuterium, in agreement with the oxidation of the primary hydroxyl group 
at C-6 in fructose to give 13 with the loss of one hydrogen atom. The introduction of the 
amino group is certainly unknown and three ways are possible through derivatives 14-
16, all of them being possible precursors of mannojirimycin 17.[44] Elimination of 
water from 17 and further reduction afforded the observed 1-deoxymannojirimycin 19. 
This route was confirmed by using 5-[
2
H]-glucose in the fermentation. Under such 
conditions deuterium was only incorporated at C-2 in mannojirimycin 17. The 1-
deoxynojirimycin 2 obtained in this experiment did not show incorporation of 
deuterium. This is in agreement with the hypothesis that either mannojirimycin 17 or its 
1-deoxy derivative 19 are precursors in the biosynthetic scheme, since loss of hydrogen 
isotope from C-2 would be expected upon epimerization of 17 or 19. Further 
experiments with deuterated substrates deomonstrated that epimerization occurs 
predominantly at nojirimycin level, i.e. between 17 and 1. It had been reported that 1-
deoxynojirimycin 2 could be epimerized to 1-deoxymannojirimycin 19 by a strain of 
Post-print de Current Chemical Biology 2014, 8, 10-16 
Agrobacterium sp. trough an oxidation to a cyclic ketocompound followed by reduction 
to give the epimeric derivative. However, by considering this hypothesis it is difficult to 
justify the presence of nojirimycin 1. 
 
 
Scheme 1. Biosynthesis of mannojirimycin 17, nojirimycin 1 and their deoxy 
derivatives 19 and 2 from D-glucose in Streptomyces subrutilus 
 
Similar experiments carried out with Bacillus subtilis var niger only produced 1-
deoxynojirimycin 2 and no traces of 1-deoximannojirimycin 19 were found.[45] Also in 
this case, labeling studies demonstrated that glucose is the precursor of 1-
deoxynojirimycin 2. Additional enzyme assays and labeling studies supported that both 
mannojirimycin 17 and nojirimycin1 are intermediates in the biosynthesis of 1-
deoxynojirimycin 2.  
Recently, the complete genome sequence of Bacillus amiloliquefaciens has been 
determined[46] and a gene cluster that initiates the biosynthesis of 2 in such 
microorganism has been identified and provided further evidence for the pathway 
illustrated in Scheme 1.[47]
 
Additionally, three enzymes involved in the first steps of 
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the biosynthesis have also been identified. Noteworthy, the same gene cluster has been 
found in Bacillus atrophaeus[48] as well as in Bacillus subtilis,[49] known producers of 
1-deoxynojirimycin 1. 
The biosynthetic route to 1-deoxynojirimycin 2 is, however, different for higher plants 
as demonstrated by Shibano and co-workers.[50] These authors studied the biosynthesis 
of 2 by using 1-[
13
C]-glucose in the higher plant Commelia communis. While a 
significant 
13
C enrichment was observed at C-6 for compound 2 obtained in 
microorganisms, in the case of that being produced in plants the 
13
C enrichment was 
located at C-1. These experiments resulted in the proposal outlined in Scheme 2. 
According to this hypothesis C-1/C-5 cyclization is produced in the original glucose 
molecule without any type of inversion. Additional support was provided by the fact 
that the same 
13






Scheme 2. Biosynthesis of nojirimycin 1 and1-deoxynojirimycin 2 from D-glucose in 
Commelia communis. 
 
When imination is produced on fructose, formed by isomerization of glucose, the same 
process led to DMDP 3 (Scheme 3). Indeed, compound 3 is obtained from 1-[
13
C]-
glucose under the same conditions employed for the preparation of 1-deoxynojirimycin 
2.[50] 
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Scheme 3. Biosynthesis of DMDP 3 from D-glucose in Commelia communis. 
 
Broussonetines are polyhydroxylated pyrrolidines bearing a long carbon chain at C-2. 
They have been isolated from Broussonetia kazinoki.[51] 
13
C NMR spectroscopy 
studies after feeding experiments using 1-[
13
C]-glucose demonstrated that broussonetine 
J 27 is synthesized through routes similar to those of sphingosine and 
phytosphingosines.[52] Similar results were obtained for broussonetines C 28 and E 29. 
 
 
Figure 3. Broussonetines 
 
Accordingly, in the case of broussonetines, it is assumed that after typical 
transformation of D-glucose into serine by well-known metabolic routes[53,54] the 
introduction of the side chain is achieved by condensation of serine with palmitoyl-
CoA. The labeling pattern found in the side chain also indicated that the palmitoyl 
fragment was formed through the acetate-malonate pathway (Scheme 4). The absolute 
configuration of the pyrrolidine moieties in most broussonetines is related to D-serine 
except in the case of broussonetine U 30 in which is related to L-serine. 
 
Post-print de Current Chemical Biology 2014, 8, 10-16 
 
Scheme 4. Biosynthesis of broussonetine J from D-glucose in Broussonetia kazinoki.  
 
3. Biosynthesis of bicyclic compounds. Indolizidines. 
 The biosynthesis of the piperidine nucleus of bicyclic iminosugars starts with the 
production of pipecolic acid, which is the precursor of several compounds such as 
swainsonine or slaframine. Pipecolic acid was found to be a product of lysine 
catabolism in animals, microorganisms and plants. Grobbelaar and Steward established 
the transformation oflysine into pipecolic acid through route A (Scheme 5) by using 
labeled lysine in bean plants Phaseolus vulgaris.[55] According to their findings the 
nitrogen of the pipecolic acid should be supplied by the α-amino group of the lysine. 
 
 
Scheme 5. Biosynthesis of pipecolic acid from lysine.  
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 On the other hand, Gupta and Spenser demonstrated that in rats  the conversion 
of lysine into pipecolic acid proceeds via ε-amino-α-ketocapric acid 35.[56] This 
mechanism indicated that the nitrogen atom of the pipecolic acid should be supplied by 
the ε-amino group of lysine (Scheme 5, route B). Similar experiments carried out with 
Neurospora crassa and Phaseolus vulgaris afforded identical results being in conflict 
with previous findings. Further studies in animals and plants demonstrated that both 
routes A and B, illustrated in Scheme 5, distinguishable at the loss of a particular amino 
group of the lysine, are possible. In fact, there are several experimental evidences 
supporting the existence of various routes in microorganisms, as well as specific 
enzymes involved in some steps. This topic has been reviewed elsewhere[57] and the 
reader is referred to that publication for more details concerning the biosynthesis of 
pipecolic acid. 
The biosynthesis of slaframine 42 has been studied in Rhizoctonia leguminicola 





C]-lysine it has been demonstrated their incorporation into 
slaframine.[59] Moreover, that incorporation was efficiently blocked by adding 
pipecolic acid, thus indicating that pipecolic acid is an intermediate in the prcess of 
biogenesis. The same authors also studied the origin of pipecolic acid in Rhizoctonia 
leguminicola and verified the biosynthetic pathway illustrated in Scheme 5.[60] Further 
experiments with radiolabelled pipecolic acid showed incorporation of radioactivity to 
slaframine in the expected positions. 
The origin of the pyrrolidine ring of slaframine was also investigated[61] and it was 
found to be formed from malonic acid and acetic acid. Spectrometric analysis of 
radiolabelled/deuterated compounds indicated that the methyl carbon of acetate is joined 
to the carboxyl carbon of the pipecolate. These results suggest the formation of 
intermediate 38 by acylation of malonate with pipecolic acid (Scheme 6). Furthermore, 
preparation of deuterated 40 allowed to identify this compound as an advanced 
intermediate in the biogenesis of slaframine[62] and to propose 1-
oxooctahydroindolizine 39 as the intermediate precursors of 40. In addition to slframine 
42, swainsonine 6 was also isolated from Rhizoctonia leguminicola.[63] By employing 
perdeutero pipecolic acid it was demonstrated that both slaframine and swainsonine 
have common precursors in their biogenesis.[64] 
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Scheme 6. Biogenesis of slaframine from lysine in Rhizoctonia leguminicola 
.  
 In the case of swainsonine, compound 39 is reduced by the other face providing 
43. Oxidation at C-8a of this intermediate should be postulated, probably through an 
iminium ion, with subsequent reduction by the appropriate face to provide the R 
configuration of swainsonine 6 (Scheme 6). Further experiments with deuterated 
compounds allowed to corroborate that hypothesis.[65]  
 The biosynthesis of swainsonine 6 has also been studied in plants. In particular, 
studies carried out with Astragalux oxyphysus showed that swainsonine 6 is 
biosynthesized in that plant by a very similar pathway (if not identical) to that in the 
fungus by incorporating pipecolic acid into the swainsonine skeleton.[66] On the other 
hand, it has been observed that the plant does not produce slaframine 42; neither does it 
produce intermediates 40 and 41. 
 The role of both pipecolic acid and malonic acid in the biosynthesis of 
swainsonine 6 has also been pointed out by stimulating production of such alkaloid by 
transformed root cultures of Swainsona galegifolia.[67] 
 
4. Conclusions 
Polyhydroxylated saturated nitrogen heterocyles provided a variety of biosynthetic 
challenges. Up to now, several aspects related to their biogenesis have been revealed. 
However, there is still much work to do. Further investigations are still required to 
clarify the biosynthetic enzymes involved in the catalytic processes. Such enzymes 
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should be of a great value for enzymatic approaches to iminosugars and their 
biomimetic synthesis. There are experimental evidences indicating that different 
biosynthetic mechanisms operate on diverse microorganisms (for instance Bacillus 
subtilis vs. Streptomyces subrutilus for 1-deoxynojirimycin) or higher plants. Very 
recently, a gene cluster has been identified providing evidence of the biosynthetic 
pathways. In this regard, the catalytic mechanism of individual domains should continue 
to be probed by using standard mutagenesis techniques with studies involving purified 
enzymes. By acquiring this knowledge it will be possible to design new analogues by 
developing more sophisticated and improved strains. The fields of synthetic organic 
chemistry and biochemistry will be united by employing new bioorganic tools for 
further chemical elaboration of new compounds of pharmaceutical interest. 
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